— ALKERMES INSPIRATION GRANTS® Program
Awards $1 Million to Non-Profit Organizations for the Development or
Expansion of Innovative Programs —
DUBLIN--(BUSINESS WIRE)--Nov. 9, 2017--
Alkermes
plc (NASDAQ: ALKS) today announced the company awarded $1 million in
grants to national and local non-profit community organizations for the
implementation of innovative, high-impact and replicable programs
designed to support people affected by mental health and substance use
disorders. Now in its second year, ALKERMES INSPIRATION GRANTS®
focuses on two key areas: improving or enhancing support or
resources for people affected by mental health concerns or substance use
disorder, and/or integrating the perspective of people affected by
mental health concerns or addiction into drug development or care
delivery.
“Addiction and mental illness affect millions of people and their
families every day, and require an integrated approach to treatment that
is scalable in communities across the country,” said Richard Pops, Chief
Executive Officer of Alkermes. “Medicines play a role, but importantly,
it is the innovative programs designed to support people affected by
these diseases and led by passionate leaders on the front lines that
will ignite sustainable and meaningful change for patients.”
Nearly 300 proposals were received from local, regional and national
non-profit organizations across the U.S. Thirteen grants were awarded to
programs demonstrating the potential for high impact and an ability for
sustainability and/or replication, and innovative and creative
approaches to support the broader needs of people in the mental health
and addiction communities. To view the full list of recipients, please
click here.
“We are again encouraged and inspired by the overwhelming number of high
quality applications to our grants program this year,” said Nikki Levy,
Vice President of Patient Engagement at Alkermes. “These organizations
are doing incredible work and help bring an important perspective to
what we do at Alkermes. We look forward to seeing the lasting impact
these organizations will have on communities affected by serious mental
illness and substance use disorders.”
“Alkermes is on the leading edge of biopharmaceutical companies who
recognize that their role and commitment to support patients and
families extend beyond developing innovative medicines,” said Kim
McCleary, Managing Director at FasterCures. “Having served on the review
committee for two years now, the breadth of unmet needs of people
affected by mental health conditions and substance use disorders is
staggering, and the novel approaches to meeting those needs at the
grassroots level are inspiring. I applaud Alkermes for prioritizing the
support of these organizations and providing funding to make innovative
programs a reality. It’s a model for meeting patients where they are and
recognizing the totality of the impact of disease on their lives and the
lives of those around them.”
Recipients were selected by an external and internal review committee,
including representatives from Alkermes, a patient advocate, a
representative from the criminal justice system, a person in recovery
and a caregiver. Proposals were evaluated based on a standard set of
review criteria, which included potential impact, identification of need
and creativity of the solution, ability to execute, and sustainability
of the program.
For more information on the ALKERMES INSPIRATION GRANTS program, please
visit www.alkermes.com/inspirationgrants.
About Alkermes
Alkermes plc is a fully integrated, global biopharmaceutical company
developing innovative medicines for the treatment of central nervous
system (CNS) diseases. The company has a diversified commercial product
portfolio and a substantial clinical pipeline of product candidates for
chronic diseases that include schizophrenia, depression, addiction and
multiple sclerosis. Headquartered in Dublin, Ireland, Alkermes plc has
an R&D center in Waltham, Massachusetts; a research and manufacturing
facility in Athlone, Ireland; and a manufacturing facility in
Wilmington, Ohio. For more information, please visit Alkermes’ website
at www.alkermes.com.
ALKERMES INSPIRATION GRANTS® is a registered service mark of
Alkermes, Inc.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171109005177/en/
Source: Alkermes plc
Alkermes Contacts:
For Investors:
Eva
Stroynowski, +1 781-609-6823
or
Sandy Coombs, +1 781-609-6377
or
For
Media:
Lindsey Smith, +1 781-609-6231